Navigation Links
New target to fight HIV infection identified
Date:10/1/2013

A mutant of an immune cell protein called ADAP (adhesion and degranulation-promoting adaptor protein) is able to block infection by HIV-1 (human immunodeficiency virus 1), new University of Cambridge research reveals. The researchers, who were funded by the Wellcome Trust, believe that their discovery will lead to new ways of combatting HIV.

Professor Chris Rudd from the Department of Pathology, who led the research, said: "One exciting aspect about this new target for HIV intervention is that we should be able to fight HIV without compromising the immune system's ability to battle infections."

HIV infections cause a severe and selective depletion of T-cells, a type of white blood cell that plays a major role in the immune system. Infections result when the HIV virus enters T-cells of the immune system by binding to the surface receptor CD4. Once it enters the cell, it replicates or reproduces itself rapidly, and then spreads to other T-cells by releasing the virus. This spread can occur between an infected T-cell and an uninfected attached T-cell. The researchers found that an ADAP mutant is able to interfere with HIV-1 infection by targeting two events, by reducing the replication of the virus, and the contact between infected and uninfected T-cells.

Professor Rudd added: "The ADAP mutant is potent in its interference of HIV-1 transmission because it targets simultaneously two critical events, viral replication and the spread of the virus from one T-cell to another. One therapeutic possibility is the reconstitution of infected individuals with T-cells expressing the mutant that are relatively resistant to HIV infection and which can react against the virus."

According the World Health Organisation, there are currently 35.3 million people living with HIV. Although the number of new HIV infections has dropped, it remains a major global public health issue. In the past three decades, it has killed more than 25 million people.


'/>"/>

Contact: Genevieve Maul
gm349@admin.cam.ac.uk
44-012-237-65542
University of Cambridge
Source:Eurekalert

Related biology news :

1. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
2. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
3. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
4. Nanobubbles plus chemotherapy equals single-cell cancer targeting
5. Researchers identify Achilles heel of dengue virus, target for future vaccines
6. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
7. Genetically modified corn affects its symbiotic relationship with non-target soil organisms
8. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
9. Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression
10. Key proteins newly discovered form and function may provide novel cancer treatment target
11. Scientists discover new inflammatory target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):
(Date:5/21/2017)... ... 20, 2017 , ... CNSDose is a genetically driven, clinically ... by finding the right antidepressant faster. CNSDose speeds recovery and reduces side ... personalized approach to treatment. , A peer-reviewed and published, 12-week double-blind ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... , ... May 17, 2017 , ... NDA Partners Chairman ... and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit ... his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM ... firm for the life sciences and healthcare industries, is honored that Jay ... Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role in ...
Breaking Biology Technology: